Accelerated action to reduce premature mortality from cancer
Growing incidences of target disease such as lung cancer, breast cancer, cervical cancer, etc. across the globe are driving the global cancer drugs market. Other major driving factors are increasing research and development on biological and targeted drug
On January 12, the US Food and Drug Administration (FDA) has granted regular approval for two anti-cancer drugs. The first one is for olaparib tablets (Lynparza, AstraZeneca Pharmaceuticals LP), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.
The other anti-cancer drug that got the approval is afatinib (Gilotrif, Boehringer Ingelheim Pharmaceutical, Inc.) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
Besides there is one more treatment that got approval from FDA on January 26 for lutetium Lu 177 dotatate (LUTATHERA, Advanced Accelerator Applications USA, Inc.) a radiolabeled somatostatin analog, for the treatment of somatostatin receptorpositive gastroenteropancreatic neuroendocrine tumors (GEPNETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. In just 30 days, from January 1, 2018 the FDA has given three approvals related to cancer treatments.
Since 2011, the FDA has given more than 10 approvals each year for anti-cancer treatments. The number of approvals has increased in last 15 years from 26 during 2003-07 period, to 70 in 2013-17. In the last 25 years the federal agency in US, responsible for protecting and promoting public health, has
approved more than 200 anti-cancer drugs. Such favourable regulatory framework is expected to boost overall product demand in the future.
The market for anticancer treatments is a booming business for the pharmaceutical industry. Nearly all of the major pharmaceutical companies are either currently manufacturing anti-cancer drugs or have anti-cancer drugs/ treatments in their pipeline as potential medications in the coming years. Cancer affects millions of people each year, and as the world population continues to grow, the rate of new cancer cases will likely grow too. Recent developments in the pharmaceutical industry have made cancer curable in many cases. Many of the newer medications are geared towards very specific kinds of cancer, charging premium prices and facing little competition. And because biologic treatments do not have the same kind of generic competition as chemical drugs, they have a longer shelf-life in terms of patent protection. This means the drug manufacturers can continue to charge whatever prices they see fit since their drugs have no generic equivalents.
The pharmaceutical industry’s 20 top-selling cancer drugs generate annual sales over $50 billion worldwide. Roche’s Rituxan, Avastin, and Herceptin lead the pack, with $21 billion in sales for these three drugs alone. Roche’s top oncology line represented about 40 per cent of the top 20 in combined sales, according to a October 2017 report by thebalance. com. There is an increasing demand worldwide for oncology medications, so pharmaceutical companies are seeing significant growth outside of their usual markets in the United States and Europe.
Rising healthcare expenditures in Asian countries like China and Japan make medications more accessible. An expanding middle class in India, partially due to the influx of pharmaceutical companies outsourcing manufacturing to Indian factories, makes more expensive medical care possible for those who can afford it. According to igeahub.com, the global oncology market is expected to grow at a rate of 7.5 per cent with top-ten companies accounting for more than one-third of the market share. Roche tops the list with three drugs in the high rankings accounting for nearly 45 per cent of the revenues. Celgene’s Revlimid is the best-selling drug also showing a 20 per cent growth rate from 2015. Interestingly, the revenue generated from the top 10 oncology drugs in 2016 increased by 13 per cent when compared with the top 10 list of 2015, thereby revealing numerous market opportunities.
According to Zion Market Research report, global cancer drugs market was valued at approximately $ 112.90 billion in 2015 and is expected to generate revenue of around $ 161.30 billion by end of 2021, growing at a CAGR of around 7.4 per cent between 2016 and 2021. North America is anticipated to remain the leading region. Demand for cancer drugs was highest in North America especially in the US. Hence, Asia Pacific is expected to be the moderate growing region in cancer drugs market. Moreover, the Middle East and Africa and Latin America are also expected to show moderate growth for this market in the years to come.
Global cancer drugs market is primarily driven by growing incidences of target disease such as lung cancer, breast cancer, cervical cancer, etc. across the globe. Other major driving factors are increasing research and development on biological and targeted drug therapies for the treatment of cancer coupled with the expiration of patents. However, the high price of drug development and stringent regulatory policies coupled with the possibility of failure are the major restraints
that may limit the growth of the market. Nonetheless increasing focus on personalized medicine along with huge investment in anti-cancer drugs research across the globe is likely to disclose the new avenues for cancer drugs market in the near future.
The anti-cancer drugs market is segmented on the basis of the different therapeutic segment including immunotherapy, targeted therapy, chemotherapy, hormone therapy and others. Recent progress in biological therapies has widened the scale of therapeutic targets for treatment of cancer with the identification of tumor cell specific genes. Immunotherapies/ biologics are emerging as potential therapies to find the permanent cure for various cancer types. Amongst various biologics, drugs based on monoclonal antibodies (mAbs) have gained significant attention in recent years due to their high efficacy further propelling the growth of oncology/ cancer drugs market.
Breast cancer, blood cancer, gastrointestinal cancer, prostate cancer, skin cancer, lung cancer and others are the key components of the global cancer drugs market. The blood cancer segment dominate the market in terms of revenue.
A majority of the oncology drug manufacturers have adopted collaboration and acquisition as key developmental strategies to achieve a competitive edge. Moreover, companies are also forming strategic alliances to accelerate the process of clinical trials. These strategies have proved to be effective in helping key market players retain their leading positions in the global oncology drugs market.
Cancer is a leading cause of death worldwide, accounting for 8.8 million deaths in 2015. And nearly every family in the world is touched by cancer, which is now responsible for almost one in six deaths globally. Between 30–50 per cent of cancers can currently be prevented by avoiding risk factors and implementing existing evidence-based prevention strategies. The cancer burden can also be reduced through early detection of cancer and management of patients who
develop cancer. Many cancers have a high chance of cure if diagnosed early and treated adequately.
To raise awareness of cancer and to encourage its prevention, detection, and treatment, World Cancer Day has been observed on February 4 each year. This international day was founded by the Union for International Cancer Control (UICC) to support the goals of the World Cancer Declaration, written in 2008. The primary goal of the World Cancer Day is to significantly reduce illness and death caused by cancer by 2020.
Founded in 1933 and based in Geneva, Switzerland, UICC (previously named International Union Against Cancer) has a membership of over 800 organisations across 155 countries, and features the world’s major cancer societies, ministries of health, research institutes and patient groups. UICC partners with its members, key partners, the World Health Organization (WHO), World Economic Forum and others, to tackle cancer on a global scale.
On World Cancer Day WHO highlights that cancer no longer needs to be a death sentence, as the capacity exists to reduce its burden and improve the survival and quality of life of people living with the disease. “All countries can do more to prevent and treat cancer,” notes Dr Etienne Krug, WHO Director for the Department for Management of Non-communicable Diseases, Disability, Violence and Injury Prevention. “We know the main causes. Acting upon them will avoid that many cases occur in the first place. By strengthening the health system response, we can also ensure earlier diagnosis and better access to affordable treatment by qualified personnel, thereby saving millions of lives.”
In May 2017, Member States came together around priority actions to ensure cancer care for all. World Health Assembly resolution WHA A70/A/CONF./9 “Cancer prevention and control in the context of an integrated approach” lays out a clear road map to realize the potential for prevention, early diagnosis, prompt treatment and palliative care for people with cancer. Since adoption of the resolution, Member States are taking action on its recommendations.
Governments are enacting evidence-based riskreducing strategies such as imposing higher taxes on tobacco and alcohol, promoting healthy diets and physical activity, and advocating for access to HPV vaccination. Approximately 30-50% of cancers can be prevented if these policies are maximally implemented.
Yet, accelerated action is needed if global targets of reducing premature mortality from cancer and ensuring universal health coverage are to be achieved. Treating cancer in its early stages is key. Today, many cases of cancer are diagnosed too late – this means they are harder to treat successfully. A renewed emphasis on strengthening health systems is needed to ensure early diagnosis and accessible, high-quality care for patients. This will result in higher cancer survival rates.
Detecting cancer early also greatly reduces cancer’s financial impact: not only is the cost of treatment much less in the early stages of cancer, but people can also continue to work and support their families if they can access effective treatment in time.
Narayan Kulkarni email@example.com